Assess the safety, tolerability and pharmacokinetics of AZD5213 after single and multiple ascending oral doses in healthy young and elderly Japanese subjects

Study identifier:D3030C00004

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5213 after Oral Administration of Single and Multiple Ascending Doses in Healthy Young and Elderly J

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD5213, Placebo

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

20 Years - 80 Years

Date

Study Start Date: 01 Apr 2011
Primary Completion Date: 01 Oct 2011
Study Completion Date: 01 Oct 2011

Study design

Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria